Results of Intravitreal Ranibizumab With a PRN Regimen in the Treatment of Extrafoveal and Juxtafoveal Neovascular Membranes in Age-Related Macular Degeneration

Giacomelli, Giovanni; Giansanti, Fabrizio; Finocchio, Lucia; Biagini, Ilaria; Bacherini, Daniela; Virgili, Gianni; Menchini, Ugo

doi:10.1097/iae.0000000000000007

Cited by 6 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although somewhat controversial [ 14 ], the efficacy of anti-VEGF therapy in extrafoveal exudative AMD has been generally encouraging [ 5 6 ]. In a study by Parodi et al [ 5 ], the mean logMAR of visual acuity improved from 0.3 at diagnosis to 0.2 at 12 months.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps

Kim

Lee

Choi

et al. 2015

Korean J Ophthalmol

View full text Add to dashboard Cite

PurposeTo evaluate the 12-month outcome of anti-vascular endothelial growth factor (VEGF) treatment for extrafoveal polypoidal choroidal vasculopathy (PCV).MethodsThis retrospective observational study included 32 eyes of 32 patients newly diagnosed with extrafoveal PCV (polyps located more than 500 µm from the center of the fovea). Patients were treated with intravitreal ranibizumab, bevacizumab, or both. The best-corrected visual acuity (BCVA) and central foveal thickness (CFT) at diagnosis and at 12 months were compared. Eyes were divided into two groups according to the presence of submacular hemorrhage. The BCVA in each group was compared at baseline and at 12 months.ResultsDuring the 12-month study period, patients received an average of 4.0 ± 1.1 anti-VEGF injections. The BCVA at baseline, three-month post-diagnosis, and 12-month post-diagnosis was 0.59 ± 0.40, 0.34 ± 0.38, and 0.38 ± 0.38, respectively. The BCVA at 12 months was significantly better than the baseline value (p = 0.002). The CFT at baseline, three-month, and 12-month post-diagnosis was 477.1 ± 194.2 µm, 214.5 ± 108.8 µm, and 229.8 ± 106.1 µm, respectively. The CFT at 12 months was significantly lower than the baseline value (p < 0.001). A significant improvement in BCVA was noted in eyes with and without submacular hemorrhage (n = 13, p = 0.032 and n = 19, p = 0.007, respectively).ConclusionsAnti-VEGF therapy was beneficial in extrafoveal PCV, regardless of the presence of submacular hemorrhage.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps

Kim

Lee

Choi

et al. 2015

Korean J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…All patients were divided into two groups: 1 + PRN (n = 51) and 3 + Q3M (n = 54). The eyes in the 1 + PRN group received intravitreal injection of conbercept one time, followed by PRN retreatment if one of the following changes were observed as previously described: 37,38 recurrent, or persistent subretinal or intraretinal fluid based on the OCT scan; new macular hemorrhage; new leakage or new onset of classic CNV on FFA; and vision loss> one line or conscious vision decrease. The eyes in the 3 + Q3M group received intravitreal injection of conbercept on three consecutive monthly, subsequently, the eyes received intravitreal injection of conbercept once every three months for three times.…”

Section: Surgical Proceduresmentioning

confidence: 99%

Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration

Liu

Zhang

Ma³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

This retrospective study aimed to analyze the clinical outcomes of two regimens of intravitreal injections of conbercept [1+pro re nata (PRN) and 3 + Q3M] for the therapy of exudative age-related macular degeneration (AMD). In total, 105 eyes diagnosed with exudative AMD were enrolled. The eyes in the 1+PRN group (n = 51) received intravitreal injection of conbercept one time, followed by PRN retreatment. The eyes in the 3 + Q3M group (n = 54) received intravitreal injection of conbercept on three consecutive monthly, subsequently, once every three months for three times. After treatment, patients were followed up for 12 months. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), and choroidal neovascularization (CNV) leakage area were compared before and after treatment. Moreover, the number of injections and adverse reactions were recorded. Compared with the 1+PRN group, BCVA was significantly improved and CRT was remarkably decreased in the 3 + Q3M group at 3, 6 and 12 months after operation. The disappeared or reduced CNV leakage area (93%) of the 3 + Q3M group was higher than that of the 1 + PRN group at the last follow-up. Moreover, the mean numbers of conbercept injections of the 1 + PRN group were less than the 3 + Q3M group. During the follow-up, there were no serious adverse reactions or ocular complications. This study reveals that intravitreal injection of conbercept using 3 + Q3M regimen has certain advantages than 1 + pRn regimen in extending drug delivery interval, improving patient's vision, and reducing CRT. Age-related macular degeneration (AMD) is one of the major causes of irreversible blindness in the elderly in the developing world 1,2. It is estimated that the prevalence of AMD among people 55 years of age and older is around 8.7% in the world 3 , and will increase in the near future since the proportion of the population over 65 years of age in developed countries is predicted to rise dramatically 4. AMD can be divided into non-exudative and exudative types, which are also known as dry or non-neovascular and wet or neovascular AMD. Although only about 10% of AMD patients have the exudative form, the incidence of severe vision impairment and blindness is as high as 80%-90% 5. One of the pathological mechanisms of exudative AMD-caused visual loss is the presence of choroidal neovascularization (CNV), the formation of aberrant new vessels arising from pre-existing choroidal 6-8. It is reported that vascular endothelial growth factor (VEGF) is a crucial regulator in CNV formation 9 and is identified as the main target for exudative AMD treatment 10. Large-scale clinical trials have confirmed that intravitreal injection of VEGF antagonists can prevent or improve vision loss in patients with exudative AMD 11-13. Conbercept (KH902; Chengdu Kanghong Biotech Co., Ltd., Sichuan, China) is the first independently developed anti-VEGF drug in China, which is a fusion protein consisting of the VEGF binding domains of VEGF receptor 1 and 2 combined with the Fc portion of the human i...

show abstract

Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration

Kim

2023

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Results of Intravitreal Ranibizumab With a PRN Regimen in the Treatment of Extrafoveal and Juxtafoveal Neovascular Membranes in Age-Related Macular Degeneration

Abstract: Other regimens described in the literature might result in a more the satisfactory outcome using more frequent follow-up and more frequent intravitreal injections.

Cited by 6 publications

References 40 publications

Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps

Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps

Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration

Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration

Contact Info

Product

Resources

About